Skip to content
value.today

Eyegate Pharmaceuticals Inc.

Total raised
$19 M
3 rounds on record
Latest round
$4 M
Jun 2016
First round on record
Dec 2009
Today
Went public
See the company page

Eyegate Pharmaceuticals Inc. is listed today as Kiora Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 7 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Eyegate Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$5 MPrivate placement after listing$2 to $10 million

Eyegate Pharmaceuticals Inc.: Private sale, Apr 2026

Investors in this round

3 investors had bought by the notice of Apr 21, 2026: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Strem · Executive Officer · President and Chief Executive Officer
  • Melissa Tosca · Executive Officer · Chief Financial Officer
  • Aron Shapiro · Director
  • Carmine Stengone · Director
  • David Hollander · Director
  • Erin Parsons · Director
  • Lisa Walters-Hoffert · Director
  • Praveen Tyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The common stock and warrants sold for a combined purchase price of $2.5429. Amount excludes any proceeds from a cash exercise of warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Melissa Tosca, Cfo. Newest notice filed Apr 21, 2026. Read the notice at the SEC.

equity, optionsSEC
Feb 2024$15 MPrivate placement after listing$10 to $50 million

Eyegate Pharmaceuticals Inc.: Private sale, Feb 2024

Investors in this round

13 investors had bought by the notice of Feb 14, 2024: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,050,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Strem · Executive Officer · President and Chief Executive Officer
  • Eric Daniels · Executive Officer · Chief Development Officer
  • Melissa Tosca · Executive Officer · Executive VP of Finance
  • Aron Shapiro · Director
  • Carmine Stengone · Director
  • David Hollander · Director
  • Erin Parsons · Director
  • Kenneth Gayron · Director
  • Praveen Tyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Amount excludes any placement agent fees payable with respect to a cash exercise of warrants.”
  • On the amounts: “The common stock and warrants sold for a combined purchase price of $0.5524. Amount excludes any proceeds from a cash exercise of warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Melissa Tosca, EVP of Finance. Newest notice filed Feb 14, 2024. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$11 MPrivate placement after listing$10 to $50 million

Eyegate Pharmaceuticals Inc.: Private sale, Aug 2021

Investors in this round

14 investors had bought by the notice of Aug 23, 2021: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$860,001
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Strem · Executive Officer, Director · President and Chief Executive Officer
  • Sarah Romano · Executive Officer · Chief Financial Officer
  • Stephen From · Executive Officer, Director · Executive Chairman
  • Aron Shapiro · Director
  • Kenneth Gayron · Director
  • Paul Chaney · Director
  • Praveen Tyle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in FL, IL, NJ, NV, NY, TX

Remarks in the notice

  • On fees: “H.C. Wainwright & Co., LLC also received warrants to purchase 233,442 warrants of common stock. The compensation also covers the sale of common stock in the concurrent registered direct offering, as well as the warrants covered by this filing.”
  • On the amounts: “This amount includes proceeds from the sale of common shares pursuant to a separate registered direct offering, as well as the warrants covered by this filing. The amount does not include proceeds from the exercise of warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for working captial and other general corporate purposes, which may include the payment of salaries and other fees to those listed in item 3.”

Signed by Sarah Romano, Chief Financial Officer. Newest notice filed Aug 23, 2021. Read the notice at the SEC.

optionsSEC
Jan 2021$8 MPrivate placement after listing$2 to $10 million

Eyegate Pharmaceuticals Inc.: Private sale, Jan 2021

Investors in this round

1 investor had bought by the notice of Jan 21, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sarah Romano · Executive Officer · Chief Financial Officer
  • Stephen From · Executive Officer, Director · President and Chief Executive Officer
  • Bernard Malfroy-Camine · Director
  • Keith Maher · Director
  • Morton Goldberg · Director
  • Paul Chaney · Director
  • Praveen Tyle · Director
  • Steven Boyd · Director
  • Thomas Hancock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Sarah Romano, Chief Financial Officer. Newest notice filed Jan 21, 2021. Read the notice at the SEC.

equity, optionsSEC
Dec 2020$3 MPrivate placement after listing$2 to $10 million

Eyegate Pharmaceuticals Inc.: Private sale, Dec 2020

Investors in this round

15 investors had bought by the notice of Jan 4, 2021: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sarah Romano · Executive Officer · Chief Financial Officer
  • Stephen From · Executive Officer, Director · President and Chief Executive Officer
  • Bernard Malfroy-Camine · Director
  • Keith Maher · Director
  • Morton Goldberg · Director
  • Paul Chaney · Director
  • Praveen Tyle · Director
  • Steven Boyd · Director
  • Thomas Hancock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “884,222 shares of common stock and 45.8923 shares of Series D Convertible Preferred Stock were issued on 12/18/2020. Additional shares may include up to $1.5 million in value of holdback shares and up to $9.5 million in value of potential earnout shares.”
  • On a merger: “This Form D relates to the issuance of shares of common stock and Series D Convertible Preferred Stock as merger consideration to the former stockholders of Panotpes Pharma G.m.b.H and its financial advisor.”

Signed by Sarah Romano, Chief Financial Officer. Newest notice filed Jan 4, 2021. Read the notice at the SEC.

equitySEC
Oct 2019$2 MPrivate placement after listingUnder $2 million

Eyegate Pharmaceuticals Inc.: Private sale, Oct 2019

Investors in this round

1 investor had bought by the notice of Oct 8, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sarah Romano · Executive Officer · CFO
  • Stephen From · Executive Officer, Director · President and CEO
  • Bernard Malfroy-Camine · Director
  • Morton Goldberg · Director
  • Paul Chaney · Director
  • Peter Greenleaf · Director
  • Praveen Tyle · Director
  • Steven Boyd · Director
  • Thomas Hancock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Stephen From, President and CEO. Newest notice filed Oct 8, 2019. Read the notice at the SEC.

equity, optionsSEC
Jun 2016$4 MNo. 3$2 to $10 million

Eyegate Pharmaceuticals Inc.: Raise no. 3, Jun 2016

Investors in this round

2 investors had bought by the notice of Jul 7, 2016: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$263,813
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ryan Brenneman · Executive Officer · Chief Financial Officer
  • Stephen From · Executive Officer, Director · President and CEO
  • Bernard Malfroy-Camine · Director
  • Morton Goldberg · Director
  • Paul Chaney · Director
  • Praveen Tyle · Director
  • Thomas Balland · Director
  • Thomas Hancock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NJ

Remarks in the notice

  • On fees: “Excludes 33,500 placement agent warrants.”
  • On the amounts: “Excludes proceeds totaling up to $2,931,250 from the exercise of the warrants.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.”

Signed by Stephen From, President and CEO. Newest notice filed Jul 7, 2016. Read the notice at the SEC.

optionsSEC
Mar 2016$3 MIssued in a merger or acquisition$2 to $10 million

Eyegate Pharmaceuticals Inc.: Private sale, Mar 2016

Investors in this round

32 investors had bought by the notice of Mar 21, 2016: 5 accredited, 27 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen From · Executive Officer, Director
  • Bernard E. Malfroy-Camine · Director
  • Morton F. Goldberg · Director
  • Mounia E. Chaoui · Director
  • Paul Chaney · Director
  • Praveen F. Tyle · Director
  • Thomas E. Hancock · Director
  • Thomas F. Balland · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Market value of the issued shares based on closing price on the date of issuance”
  • On a merger: “"On March 7, 2016, the Company entered into a Stock Purchase Agreement. The Company acquired 100% of the outstanding equity interests of Jade Therapeutics, Inc. (""Jade"") and Jade became a wholly-owned subsidiary of the Company."”

Signed by Stephen From, President & Chief Executive Officer. Newest notice filed Mar 21, 2016. Read the notice at the SEC.

equitySEC
Dec 2010$4 MNo. 2$2 to $10 million

Eyegate Pharmaceuticals Inc.: Raise no. 2, Dec 2010

Investors in this round

9 investors had bought by the notice of Jan 5, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$9,999
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen From · Executive Officer, Director
  • Alain Maiore · Director
  • Laurent Assaraf · Director
  • Michael Patane · Director
  • Morton Goldberg · Director
  • Paul Chaney · Director
  • Praveen Tyle · Director
  • Thomas Hancock · Director
  • Walter Meier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen From, President. Newest notice filed Jan 5, 2011. Read the notice at the SEC.

equitySEC
Dec 2009$11 MNo. 1$10 to $50 million

Eyegate Pharmaceuticals Inc.: Raise no. 1, Dec 2009

Investors in this round

20 investors had bought by the notice of Dec 21, 2009: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Eyegate Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $23 M offered; $12 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen From · Executive Officer, Director
  • Alain Sebastien Maiore · Director
  • J. Sebastien Cleftie · Director
  • Michael Sebastien Mullen · Director
  • Morton E. Goldberg · Director
  • Paul E. Chaney · Director
  • Praveen E. Tyle · Director
  • Thomas E. Hancock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount includes investments made by foreign entities.”

Signed by Stephen From, President. Newest notice filed Dec 21, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Kiora Pharmaceuticals, Inc., its revenue in fiscal 2024 came from these business segments: Reportable $16.02 million (100%).

    Annual report (SEC XBRL) · Dec 2024

  • Eyegate Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).

    SEC Form D · Apr 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2026

Products and services#

No products or services of Eyegate Pharmaceuticals Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Eyegate Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Armistice Capital, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Armistice Capital Master Fund Ltd.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Ipsa (innoven Partenaires S.A.)Companynot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Ventech B. FcprPersonnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Ventech Capital IIFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Largest shareholders today

Institutions holding Kiora Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Eyegate Pharmaceuticals Inc.
NameRoleNamed in
Brian StremPresident and Chief Executive OfficerApr 2026
Melissa ToscaChief Financial OfficerApr 2026
Eric DanielsChief Development OfficerFeb 2024
Sarah RomanoChief Financial OfficerAug 2021
Stephen FromExecutive ChairmanAug 2021
Ryan BrennemanChief Financial OfficerJul 2016
Aron ShapiroDirectorApr 2026
Carmine StengoneDirectorApr 2026
David HollanderDirectorApr 2026
Erin ParsonsDirectorApr 2026
Lisa Walters-HoffertDirectorApr 2026
Praveen TyleDirectorApr 2026
Kenneth GayronDirectorFeb 2024
Brian StremPresident and Chief Executive OfficerAug 2021
Paul ChaneyDirectorAug 2021
Stephen FromExecutive ChairmanAug 2021
Bernard Malfroy-CamineDirectorJan 2021
Keith MaherDirectorJan 2021
Morton GoldbergDirectorJan 2021
Steven BoydDirectorJan 2021
Thomas HancockDirectorJan 2021
Peter GreenleafDirectorOct 2019
Thomas BallandDirectorJul 2016
Bernard E. Malfroy-CamineDirectorMar 2016
Morton F. GoldbergDirectorMar 2016
Mounia E. ChaouiDirectorMar 2016
Praveen F. TyleDirectorMar 2016
Thomas E. HancockDirectorMar 2016
Thomas F. BallandDirectorMar 2016
Alain MaioreDirectorJan 2011
Laurent AssarafDirectorJan 2011
Michael PataneDirectorJan 2011
Walter MeierDirectorJan 2011
Alain Sebastien MaioreDirectorDec 2009
J. Sebastien CleftieDirectorDec 2009
Michael Sebastien MullenDirectorDec 2009
Morton E. GoldbergDirectorDec 2009
Paul E. ChaneyDirectorDec 2009
Praveen E. TyleDirectorDec 2009

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.